SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31

ARS Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$4.23+0.21 (+5.22%)

Close on Oct 19, 2026

Market cap: $420.09M
P/E (TTM): –
Dividend yield: –

ARS Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	84	89	0.03	1.32	5.51	–
Cost of Revenue	–	–	0	–	–	–
Gross Profit	–	–	0.03	–	–	–
Research & Development	13	20	20	18	20	25
Selling, General & Admin	230	72	47	0.60	–	–
General & Administrative	–	–	47	18	4.69	8.34
Advertising Expenses	100	13	–	–	–	–
Operating Expenses	264	92	68	37	25	33
Operating Income	-179	-3.08	-68	-36	-19	-33
Other Non-Operating Income	8.07	11	13	0.97	-0.79	–
Gain (Loss) on Investments	–	–	0	-0.14	0	–
Pretax Income	-171	8.29	-54	–	–	–
Income Tax Expense	-0.08	0.29	0	0	0	0
Net Income	-171	8.00	-54	-35	-20	-33
EPS (Basic)(per share)	-1.74	0.08	-0.57	-0.87	-0.70	-11.33
EPS (Diluted)(per share)	-1.74	0.08	-0.57	-0.87	-0.70	-11.33
Shares Outstanding (Basic, Weighted)(shares)	99	97	95	40	29	2.91
Shares Outstanding (Diluted, Weighted)(shares)	99	102	95	40	29	2.91
EBITDA	-178	-3.00	-67	-35	-19	–
Net Interest Income	–	–	–	–	0.11	-0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -185.0%
Net margin: -184.2%
Return on equity, FY2025: -92.3%

Financial strength

Current ratio: 3.48
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 13.4%

Valuation

P/E ratio: –
Price to sales: 3.59
Price to book: 33.58
Dividend yield: –